Thymosin Alpha-1 + Thymalin Blend
How this combination works
The community rationale pairs two thymus-derived immunomodulators: Thymosin Alpha-1, a single defined 28-amino-acid peptide with human RCT data in sepsis, hepatitis B and vaccine response (see its peptide page), and Thymalin, a thymic polypeptide complex studied mostly in Russian observational and in vitro work. Both are proposed to support T-cell maturation and function, so the pairing is overlapping rather than complementary. Whether combining them adds anything over either alone has not been studied. This rationale is mechanistic inference only.
Combined mechanism
Thymosin Alpha-1 acts through Toll-like receptors, especially TLR7, in myeloid and plasmacytoid dendritic cells. It stimulates T-cell differentiation and proliferation, increases thymic output and restores exhausted T cells, and suppresses myeloid-derived suppressor cells. Thymalin is a polypeptide complex extracted from the thymus. Its dipeptide components KE and EW stimulate cellular immunity and lower IL-1β, IL-6 and TNF-α in human mononuclear cells in vitro. It promotes maturation of CD117+ stem cells into CD28+ T lymphocytes. Both compounds converge on T-cell maturation and function. No human pharmacokinetic or pharmacodynamic data exist for the combination.
What each component does
Evidence base for this combination
Safety considerations for this combination
- No combination-specific safety data exist for Thymosin Alpha-1 + Thymalin. The signals below come from each compound studied on its own. Component approved files
- Thymalin is an extract from bovine thymus, not a single defined molecule, so composition can vary between preparations. Thymalin: PMID: 37686182
- Thymalin therapy was 'not conducive to a rapid abatement of acute symptoms' in herpetic stomatitis, suggesting limited acute efficacy in some conditions and a need to weigh expected benefits against timing of response Inherited from Thymalin (PMID: 8191521)
- In dysentery patients, thymalin (unlike indomethacin) inhibited antigen-specific T-lymphocyte adhesiveness while normalizing nonspecific adhesiveness — differential immunomodulatory effects may not be uniformly beneficial across all immune parameters Inherited from Thymalin (PMID: 2441548)
- Thymalin exerted 'no substantial effect' on chemotaxis and phagocytosis of leukocytes, content of immunoglobulins, or circulating immune complexes in non-specific pulmonary disease patients — efficacy appears selective and not universal across all immune functions Inherited from Thymalin (PMID: 2741122)
- In COVID-19 severe patients, hospital mortality in the Thymalin group was 20.6%, indicating that a substantial proportion of treated patients still died despite Thymalin use — it is not curative in severe disease Inherited from Thymalin (PMID: 36169363)
- Thymosin Alpha-1's approved file lists no compound-specific safety signals. That reflects limited study, not established safety; see the Thymosin Alpha-1 peptide page. Thymosin Alpha-1 approved file
Contraindications
- Both compounds modulate immune activity. Use in autoimmune disease, in transplant recipients or alongside immunosuppressive therapy has not been studied for either compound alone or for the combination; this is a mechanistic caution, not a documented interaction. Mechanistic inference from PMID: 27442287 (Tα1) and 33237528 (Thymalin)
- As of 2023 the FDA restricted Thymosin Alpha-1 from compounding. Thymalin's FDA status is not stated in its reviewed literature. Thymosin Alpha-1: PMID: 38308608
- Thymosin Alpha-1 + Thymalin has not been evaluated as a combination in any clinical trial. The lack of combination-specific contraindications reflects that absence of study, not established safety. No combination study cited in either component file